World's Best Scientists 2026 revealed!
Alberto Bardelli

Alberto Bardelli

D-Index & Metrics

Medicine

D-Index
122
Citations
82479
World Ranking
3407
National Ranking
98

Alberto Bardelli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alberto Bardelli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 461 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alberto Bardelli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alberto Bardelli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the European Molecular Biology Organization (EMBO)

Overview

Alberto Bardelli is affiliated with the University of Turin in Italy and has a significant body of research concentrated in medicine, particularly within oncology and molecular biology. Their publication record includes extensive work in cancer genomics, diagnostics, and colorectal cancer treatments, reflecting a focused interest in the genetic factors underlying colorectal cancer and related therapies.

Their research spans various subfields, with a high concentration in oncology, molecular biology, cancer research, pathology and forensic medicine, and pulmonary and respiratory medicine.

Frequent publication venues for Bardelli include Cancer Research, Annals of Oncology, Cancer Discovery, Cancers, and the Journal of Clinical Oncology, illustrating sustained contributions to prominent journals in the oncology and medical research communities.

Key recent publications authored by or involving Bardelli are:

  • EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer, 2020, Cancer Discovery
  • High-dose vitamin C enhances cancer immunotherapy, 2020, Science Translational Medicine
  • Precision oncology in metastatic colorectal cancer - from biology to medicine, 2021, Nature Reviews Clinical Oncology
  • Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial, 2022, Nature Medicine
  • The status of tumor mutational burden and immunotherapy, 2022, Nature Cancer

Among frequent co-authors of Bardelli are Salvatore Siena, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Silvia Marsoni, and Giovanni Crisafulli. These collaborators have contributed to a range of research efforts spanning cancer genomics and treatment strategies.

Main topics of Bardelli's work cover:

  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Cancer Immunotherapy and Biomarkers
  • DNA Repair Mechanisms
  • Lung Cancer Treatments and Mutations
  • Melanoma and MAPK Pathways

Alberto Bardelli is recognized as a member of the European Molecular Biology Organization (EMBO).

Best Publications

  • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Chetan Bettegowda;Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde

  • High frequency of mutations of the PIK3CA gene in human cancers

    Yardena Samuels;Zhenghe Wang;Alberto Bardelli;Natalie Silliman

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Liquid Biopsies: Genotyping Circulating Tumor DNA

    Luis A. Diaz;Alberto Bardelli

  • International network of cancer genome projects

    Thomas J. Hudson;Thomas J. Hudson;Warwick Anderson;Axel Aretz;Anna D. Barker

  • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

    Anirudh Prahallad;Chong Sun;Sidong Huang;Federica Di Nicolantonio

  • Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

    Federica Di Nicolantonio;Miriam Martini;Francesca Molinari;Andrea Sartore-Bianchi

  • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

    Sandra Misale;Rona Yaeger;Sebastijan Hobor;Elisa Scala

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Liquid biopsy: monitoring cancer-genetics in the blood.

    Emily Crowley;Federica Di Nicolantonio;Fotios Loupakis;Alberto Bardelli

  • Integrating liquid biopsies into the management of cancer

    Giulia Siravegna;Silvia Marsoni;Salvatore Siena;Alberto Bardelli

  • Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.

    Harith Rajagopalan;Alberto Bardelli;Christoph Lengauer;Kenneth W. Kinzler

  • A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

    Carola Ponzetto;Alberto Bardelli;Alberto Bardelli;Zhu Zhen;Flavio Maina

  • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

    Mauro Moroni;Silvio Veronese;Silvia Benvenuti;Giovanna Marrapese

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

    Giulia Siravegna;Benedetta Mussolin;Michela Buscarino;Giorgio Corti

  • Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

    Silvia Benvenuti;Andrea Sartore-Bianchi;Federica Di Nicolantonio;Carlo Zanon

  • A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

    Andrea Bertotti;Giorgia Migliardi;Francesco Galimi;Francesco Sassi

  • Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

    Aaron N. Hata;Matthew J. Niederst;Hannah L. Archibald;Maria Gomez-Caraballo

  • PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

    Andrea Sartore-Bianchi;Miriam Martini;Francesca Molinari;Silvio Veronese

Frequent Co-Authors

Salvatore Siena
Salvatore Siena University of Milan
Andrea Sartore-Bianchi
Andrea Sartore-Bianchi University of Milan
Paolo M. Comoglio
Paolo M. Comoglio FIRC Institute of Molecular Oncology
Enzo Medico
Enzo Medico University of Turin
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Filippo de Braud
Filippo de Braud University of Milan
Bert Vogelstein
Bert Vogelstein Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require a traditional path. Many students today are opting for alternative, flexible online degrees in health-related fields. If you're interested in blending technology and care, an online MHI (Master of Health Information) program can open doors to roles involving medical data management and health IT, all while studying remotely.

Those looking for fast-track entry into healthcare can consider medical billing and coding online courses cost comparisons. These programs lead to essential support roles in clinics and hospitals and can often be completed quickly and affordably.

More advanced online clinical options include nursing. For aspiring nurse practitioners, the cheapest nurse practitioner programs offer the chance to specialize and take on greater patient care responsibilities—all with flexibility for working professionals.

If a foundational nursing degree is your goal, plenty of cheapest online BSN programs are now available, making it more convenient and affordable than ever to start a rewarding nursing career.

Best Scientists Citing Alberto Bardelli

Trending Scientists

Recently Published Articles